Accessibility Menu
Fate Therapeutics Stock Quote

Fate Therapeutics (NASDAQ: FATE)

$1.52
(-1.3%)
-0.02
Price as of October 21, 2025, 3:21 p.m. ET

KEY DATA POINTS

Current Price
$1.52
Daily Change
(-1.3%) $0.02
Day's Range
$1.43 - $1.56
Previous Close
$1.54
Open
$1.52
Beta
1.60
Volume
925,750
Average Volume
1,979,444
Market Cap
177.6M
Market Cap / Employee
$1.54M
52wk Range
$0.66 - $3.5
Revenue
-
Gross Margin
-0.89%
Dividend Yield
N/A
EPS
-$1.45
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Fate Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
FATE-52.32%-96.54%-48.96%-77%
S&P+14.84%+96.04%+14.41%+297%

Fate Therapeutics Company Info

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.91M-71.8%
Gross Profit-$1.37M-166.8%
Gross Margin-71.89%-102.2%
Market Cap$128.39M-65.6%
Market Cap / Employee$0.71M0.0%
Employees1810.0%
Net Income-$34.07M11.3%
EBITDA-$33.69M16.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$41.25M11.7%
Accounts Receivable$1.40M33.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$75.68M-19.4%
Short Term Debt$5.66M-14.9%

Ratios

Q2 2025YOY Change
Return On Assets-38.10%-6.5%
Return On Invested Capital-38.52%-2.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$25.95M19.8%
Operating Free Cash Flow-$24.59M23.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book1.100.520.280.45-49.19%
Price to Sales30.6514.267.0115.67-49.90%
Price to Tangible Book Value1.100.520.280.45-49.19%
Enterprise Value to EBITDA-4.49-0.011.680.26-105.79%
Return on Equity-46.6%-54.2%-49.2%-52.1%23.76%
Total Debt$98.98M$85.27M$83.33M$81.33M-19.12%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.